Tag Archive for: #Synaffix

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at […]

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry. Read more…

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead […]

Genmab and Synaffix Enter into License Agreement for ADC Technology

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion

Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660) AMSTERDAM, NETHERLANDS, November 30, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the […]